Literature DB >> 18504289

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients.

C Charlier1, C Henegar, O Launay, C Pagnoux, A Berezné, B Bienvenu, P Cohen, L Mouthon, L Guillevin.   

Abstract

OBJECTIVE: To characterise major infectious complications and analyse potential risk factors in patients with Wegener granulomatosis (WG).
METHODS: Data from 113 patients with WG (69 male) followed at least once between January 1984 and March 2006 in our internal medicine department, were analysed retrospectively.
RESULTS: A total of 35 patients (mean (SD) age at WG diagnosis: 50.2 (13.05) years) developed 53 major infections. Infections were: bronchopneumonias (n = 19), herpes zoster recurrences (n = 9), cellulitis (n = 4), prostatitis (n = 4), spondylodiscitis and septic arthritis (n = 3), digestive tract infections (n = 2), Enterococcus faecalis or Staphylococcus aureus septicaemia (n = 2), viral hepatitis B reactivations (n = 2), post transfusion HIV infection with fatal cerebral toxoplasmosis, oesophageal candidiasis, disseminated herpes simplex and cytomegalovirus infection, cytomegalovirus retinitis, herpetic keratitis, herpetic stomatitis, Serratia sp. node suppuration and fever resolving under broad spectrum antibiotics (n = 1 each). Half of the major infectious episodes occurred within 3 years after WG diagnosis. Eight (7%) patients died, with two (2%) infection-related deaths. Patients diagnosed with WG before 1996 had a significantly higher rate of infection than those diagnosed later (48% vs 24%, p = 0.02). Cyclophosphamide and corticosteroids were independently associated with significantly higher risk of major infection (p<0.05 and <0.001, respectively). All patients treated since 1993 received antipneumocystosis prophylaxis.
CONCLUSION: Cyclophosphamide and corticosteroids were associated with higher risk of infection. Despite systematic cotrimoxazole prophylaxis, major infections, mostly bronchopneumonias and herpes zoster recurrences, were still common in the course of WG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504289     DOI: 10.1136/ard.2008.088302

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  39 in total

Review 1.  Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors:  Nadezhda Wall; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

3.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

Review 4.  Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression.

Authors:  Alessandra Soriano; Nazareno Smerieri; Stefano Bonilauri; Loredana De Marco; Alberto Cavazza; Carlo Salvarani
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

5.  Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.

Authors:  Pali D Shah; Qiong Zhong; Elizabeth A Lendermon; Matthew R Pipeling; John F McDyer
Journal:  Viral Immunol       Date:  2015-05-18       Impact factor: 2.257

Review 6.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

7.  Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.

Authors:  Valentin S Schäfer; Tanaz A Kermani; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

8.  Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis.

Authors:  Juyoung Yoo; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

9.  Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

Authors:  Rémi Goupil; Soumeya Brachemi; Annie-Claire Nadeau-Fredette; Clément Déziel; Yves Troyanov; Valery Lavergne; Stéphan Troyanov
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

Review 10.  Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.

Authors:  Ágnes Haris; Szilveszter Dolgos; Kálmán Polner
Journal:  Int Urol Nephrol       Date:  2016-09-26       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.